The relationship between healthy lifestyle behaviors and the incidence of IBS.
Novartis preps Kisqali for FDA; Ventyx cuts 20% of workers; Keytruda plus Lenvima hits PhIII setback
Plus news about Rigel Pharmaceuticals collaborating with MD Anderson. Novartis updates PhIII data for Kisqali: The company has already filed the NATALEE data with the EMA